On July 25, 2023, the Board of Directors of Homology Medicines, Inc. approved a reduction in the Company?s current workforce by approximately 80 employees. The decision was based on cost-reduction initiatives intended to reduce the Company?s ongoing operating expenses and maximize shareholder value as the Company plans to pursue strategic options.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.02 USD | -0.78% | +24.59% | +156.03% |
Apr. 11 | Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target | MT |
Apr. 03 | Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+156.03% | 334M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- QTTB Stock
- News Q32 Bio Inc.
- Homology Medicines, Inc. Approves Reduction in Workforce